Celgene Corporation (CELG) Stock Looks Like a Winner

Celgene (CELG) stock jumped over 30% in the past few trading days — and with good reason. Investors are excited over what is …

Celgene (CELG) Investment in Acceleron (XLRN) Now Bearing Fruit; Cowen Weighs In

In September last year, Celgene (NASDAQ:CELG) bought 750,000 shares of Acceleron Pharma (NASDAQ:XLRN), and for a good reason. Celgene is Acceleron’s largest holder and …

Investing Guru Philip Hempleman Clears Out of Helios and Matheson (HMNY), Takes Off Full Speed in Celgene (CELG)

Ardsley fund manager Philip Hempleman has fled out of HMNY, but walked into a new position in CELG, as of the most recent SEC filing.

RBC Capital Makes a Bullish Case for Celgene (CELG) Amid Overblown Share Weakness

RBC Capital’s Brian Abrahams believes that the exit of Celgene’s former BD chief is causing an unwarranted dip in the stock; here’s why.

Oppenheimer Comments on Celgene (CELG) After ASCO Abstracts Reveal

The annual meeting of the American Society of Clinical Oncology (commonly known as ASCO) is around the corner. As usual, abstracts get released …

Celgene (CELG) Gets Two Votes of Confidence from Oppenheimer and Canaccord Following Q1 Update

Oppenheimer’s Leah R. Cann and Canaccord’s John Newman are out with bullish research notes following this biotech giant’s first quarter print.

Celgene Corporation (CELG): The Issue with the Rejection of Relapsing MS Candidate Boils Down to Visibility

Cantor’s Mara Goldstein says growth beyond 2020 for CELG just got cloudy with the FDA’s RTF letter for ozanimod.

2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc (JUNO), Celgene Corporation (CELG)

Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion or $87/share (net of the ~10% it …

Juno Therapeutics Inc (JUNO) Spikes on Rumors of Celgene Takeover; Analysts Dive in

Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.

Celgene Corporation (CELG) Discontinuation Impairment Charge from Failed Crohn’s Drug Program Is Ultimately ‘Insignificant’

Cantor’s Mara Goldstein is not shaken by the $411 million pretax charge impacting CELG in 4Q, as the stock barely dipped past 1% upon the GED-0301 program cancellation news.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts